Art. 59 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2022cited 3×
1.

The Agency shall take care to ensure early identification of potential sources of conflict between its scientific opinions and those of other bodies established under Union law carrying out a similar task in relation to issues of common concern.

2.

Where the Agency identifies a potential source of conflict, it shall contact the body concerned in order to ensure that any relevant scientific information is shared and to identify the scientific points which potentially conflict.

3.

Where there is a fundamental conflict over scientific points and the body concerned is a Union agency or a scientific committee, the Agency and the body concerned shall work together either to resolve the conflict or to submit a joint document to the Commission clarifying the scientific points of conflict. This document shall be published immediately after its adoption.

4.

Unless otherwise provided for in this Regulation, Regulation (EU) 2019/6 or Directive 2001/83/EC, where there is a fundamental conflict over scientific points and the body concerned is a body in a Member State, the Agency and the national body concerned shall work together either to resolve the conflict or to prepare a joint document clarifying the scientific points of conflict. Such joint document shall be published immediately after its adoption.

  • Regulation (EU) 2019/5Lawamends

  • Judgment of the Court (Third Chamber) of 22 June 2023. Federal Republic of Germany v European Commission.Decision

    Title IV of Regulation No 726/2004, entitled ‘The European Medicines Agency – Responsibilities and administrative structure’, includes a Chapter 1, itself entitled ‘Tasks of the agency’, comprising Articles 55 to 66 of that same …

    22 Jun 2023 · 62021CJ0006

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    La requérante estime que, en refusant l’octroi de l’AMM conditionnelle en considérant que « le rapport bénéfice/risque [de l]’Hopveus n’[était] pas favorable », la Commission a entaché la décision attaquée d’une …

    2 Mar 2022 · 62020TJ0556